NASDAQ:JAGX Jaguar Animal Health Q3 2026 Earnings Date & Estimates $2.64 -0.19 (-6.56%) Closing price 03:59 PM EasternExtended Trading$2.67 +0.03 (+1.21%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jaguar Animal Health is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Jaguar Animal Health in Q3 2026Jaguar Animal Health is expected to post earnings of -$444.2941 per share on revenue of $4.85 million. In the same quarter a year earlier Jaguar Animal Health reported -$3,297.00 per share on revenue of $3.08 million. Jaguar Animal Health last reported on August 19, 2026, posting -$15.70 per share and beating the -$782.25 consensus estimate.Consensus EstimatesConsensus EPS-$444.2941Expected Revenue$4.85 millionPrior-Year EPS-$3,297.00Prior-Year Revenue$3.08 millionExpected Revenue Growth+57.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$15.70 (Beat by +$766.55)Last Quarter Revenue$1.23 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Jaguar Animal Health Q3 2026 Earnings FAQ When does Jaguar Animal Health report Q3 2026 earnings? Jaguar Animal Health (NASDAQ:JAGX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Jaguar Animal Health's Q3 2026 earnings call? Jaguar Animal Health's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Jaguar Animal Health? Analysts expect Jaguar Animal Health to post earnings of -$444.2941 per share for Q3 2026. How much revenue is Jaguar Animal Health expected to report? The consensus revenue estimate for Jaguar Animal Health is $4.85 million for Q3 2026. Jaguar Animal Health Earnings HeadlinesJaguar Animal Health (NASDAQ:JAGX) vs. Adherex Technologies (NASDAQ:FENC) Financial ContrastOctober 20 at 4:29 AM | americanbankingnews.comReminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendOctober 13, 2026 | theglobeandmail.comI waited 13 years for this setupGold more than doubled after breaking a 13-year range in April 2024, then fell over 20 percent in its worst quarter since 2013. This isn't the first time. In 2008, gold dropped hard mid-supercycle, and three years later it neared 2,000 dollars. The biggest gains came from an overlooked backdoor gold play that ran as high as 1,915 percent during that cycle. Ross Givens believes this supercycle is far from over.October 20 at 1:00 AM | Traders Agency (Ad)Jaguar Animal Health, Inc. (NASDAQ:JAGX) Shares Shorted: Short Interest Down 74.2% in SeptemberOctober 11, 2026 | americanbankingnews.comJaguar Animal Health (NASDAQ:JAGX) Share Price Breaks Below Fifty Day Moving Average - Time to Sell?October 10, 2026 | americanbankingnews.comWall Street Zen Upgrades Jaguar Animal Health (NASDAQ:JAGX) to SellOctober 10, 2026 | americanbankingnews.comSee More Jaguar Animal Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email. Email Address About Jaguar Animal HealthJaguar Animal Health (NASDAQ:JAGX) is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America. The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S. Food and Drug Administration for the management of chemotherapy-induced diarrhea in dogs. Jaguar has also pursued additional applications for crofelemer and related gastrointestinal treatments in veterinary medicine, including products intended to address diarrhea and other digestive conditions. Jaguar’s broader business has included research and development activities through its Napo Pharmaceuticals subsidiary, which focuses on plant-derived medicines for gastrointestinal disorders in humans. The company works with commercial and research partners to support product development and distribution in the United States and selected international markets. Jaguar Animal Health was founded by Lisa Conte, who serves as its president and chief executive officer.View Jaguar Animal Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Halliburton Gains Traction: Multiyear Upcycle AheadMeta Platforms' AI Comeback Faces an Earnings Test—And a $10 Billion ChargeCarMax's Double Upgrade Could Signal a Bigger TurnaroundD-Wave Stock Has 2 New Reasons for Investors to Pay AttentionTesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging Upcoming Earnings Meta Platforms (10/21/2026)AT&T (10/21/2026)Tesla (10/21/2026)Philip Morris International (10/21/2026)Kinder Morgan (10/21/2026)CME Group (10/21/2026)Moody's (10/21/2026)Abbott Laboratories (10/21/2026)Danaher (10/21/2026)Elevance Health (10/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
